Reappraisal of recent clinical trials of angiogenic therapy in myocardial ischemia

Asian Cardiovascular and Thoracic Annals

Volumn 13, Issue 1, 2005, Pages 90-97

  Teng, Carolyn J ^a   Lachapelle, Kevin ^a   Chiu, Ray C J ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANGIOPOIETIN RECEPTOR; BASIC FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; GLYCERYL TRINITRATE; HEPARIN; PLACEBO; PLASMID DNA; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR 2; RECOMBINANT VASCULOTROPIN; TIE 1 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN C;

ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ANGIOGENESIS; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG MEGADOSE; FOLLOW UP; GENE OVEREXPRESSION; GENETIC CODE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HUMAN; LOW DRUG DOSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROTEIN PROTEIN INTERACTION; REVIEW; TREADMILL EXERCISE; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM;

EID: 18144371110     PISSN: 02184923     EISSN: None     Source Type: Journal    
DOI: 10.1177/021849230501300124     Document Type: Review

References (40)

1. Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR, et al. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg 1999;230:466-70.
2. 165 as sole therapy for myocardial ischemia. Circulation 1998;98:2800-4.
3. Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Mayskiy M, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 1999;68:830-6.
4. 165 gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 2000;102:965-74.
5. Lathi KG, Vale PR, Losordo DW, Cespedes RM, Symes JF, Esakof DD, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results. Anesth Analg 2001;92:19-25.
6. Losordo DW, Vale PR, Hendel RC, Milliken CE, Fortuin FD, Cummings N, et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002;105:2012-8.
7. Fortuin FD, Vale P, Losordo DW, Symes J, DeLaria GA, Tyner JJ, et al. One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients. Am J Cardiol 2003;92:436-9.
8. Hendel RC, Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect [see comment]. Circulation 2000;101:118-21.
9. Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, Simons M, et al. Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J 2001;142:872-80.
10. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003;107:1359-65.
11. Schumacher B, Pecher P, von Specht BU, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease [see comment]. Circulation 1998;97:645-50.
12. Pecher P, Schumacher BA. Angiogenesis in ischemic human myocardium: clinical results after 3 years [see comment]. Ann Thorac Surg 2000;69:1414-9.
13. Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg 1998;65:1540-4.
14. Ruel M, Laham RJ, Parker JA, Post MJ, Ware JA, Simons M, et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg 2002;124:28-34.
15. Laham RJ, Chronos NA, Pike M, Leimbach ME, Udelson JE, Pearlman JD, et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. J Am Coll Cardiol 2000;36:2132-9
16. Udelson JE, Dilsizian V, Laham RJ, Chronos N, Vansant J, Blais M, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 2000;102:1605-10.
17. Unger EF, Goncalves L, Epstein SE, Chew EY, Trapnell CB, Cannon RO, 3rd, et al. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am J Cardiol 2000;85:1414-9.
18. Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-93.
19. Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris [see comment]. Circulation 2002;105:1291-7.
20. Kutryk MJ, Stewart DJ. Angiogenesis of the heart [review]. Microsc Res Tech 2003;60:138-58.
21. McMahon JM, Wells KE, Bamfo JE, Cartwright MA, Wells DJ. Inflammatory responses following direct injection of plasmid DNA into skeletal muscle. Gene Ther 1998;5:1283-90.
22. Hiromatsu Y, Toda S. Mast cells and angiogenesis [review]. Microsc Res Tech 2003;60:64-9.
23. Iijima K, Yoshikawa N, Nakamura H. Activation-induced expression of vascular permeability factor by human peripheral T cells: a non-radioisotopic semiquantitative reverse transcription-polymerase chain reaction assay. J Immunol Methods 1996;196:199-209.
24. Scapini P, Calzetti F, Cassatella MA. On the detection of neutrophil-derived vascular endothelial growth factor (VEGF). J Immunol Methods 1999;232:121-9.
25. Gaudry M, Bregerie O, Andrieu V, El Benna J, Pocidalo MA, Hakim J. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood 1997;90:4153-61.
26. Laham RJ, Rezaee M, Post M, Sellke FW, Braeckman RA, Hung D, et al. Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. Drug Metab Dispos 1999;27:821-6.
27. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000;102:898-901.
28. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62-6.
29. Fong GH, Zhang L, Bryce DM, Peng J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development 1999;126:3015-25.
30. Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, Auerbach A, et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 1994;8:1897-909.
31. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995;376:70-4.
32. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis [see comment]. Cell 1996;87:1171-80.
33. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis [see comment]. Science 1997;277:55-60.
34. Schattemann GC, Loushin C, Li T, Hart CE. PDGF-A is required for normal murine cardiovascular development. Dev Biol 1996;176:133-42.
35. Jain RK. Molecular regulation of vessel maturation [review]. Nat Med 2003;9:685-93.
36. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999;286:2511-4.
37. Hellstrom M, Gerhardt H, Kalen M, Li X, Eriksson U, Wolburg H, et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 2001;153:543-53.
38. Loughna S, Sato TN. Angiopoietin and Tie signaling pathways in vascular development [review]. Matrix Biol 2001;20:319-25.
39. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation [review]. Nature 2000;407:242-8.
40. Chambers RC, Leoni P, Kaminski N, Laurent GJ, Heller RA. Global expression profiling of fibroblast responses to transforming growth factor-beta1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching. Am J Pathol 2003;162:533-46.